anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical material which can securely obstruct accretion regardless of tissue and position.  &lt;P&gt;SOLUTION: The medical material for obstructing accretion has a skeleton as a structure comprising a biocompatible base material and containing more than 40 wt.% of polyol therein. As the biocompatible base material, an in vivo non-decomposing absorptive substance selected from polyester, polyurethane, polyamide, silicone resin, and fluorine containing polymer, or a base material selected from such as polysaccharide such as collagen, cellulose, carboxymethyl cellulose, chitin, chitosan, starch, amylose, amylopectin, dextrin and in vivo decomposing absorptive substances such as polyvinyl alcohol, polyethylene glycol, polycaprolactone, polylactic acid, polyglycollic acid, polycaproic acid, polymethylene carbonate are preferable. As the polyol, polyethylene glycol, xylitol, sorbitol, glycerine, etc. are preferable.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention pertains to oil-in-water emulsion compositions having hydrophobic materials stably dispersed therein and methods for making such. The preferred method of making the emulsion compositions the formation of two O/W emulsions. A first O/W emulsion is for wetting or otherwise pre-treating the hydrophobic components. Thereafter, the first emulsion is added to a second O/W emulsion after the second emulsion has been formed. Both emulsions use a ternary surfactant blend of cationic, anionic and bridging surfactants, making the finished product a double or &#39;binary-CAN&#39; emulsion system. Generally, the system has a bi-modal oil droplet distribution.
Novel means have been discovered for increasing the resistance of a mammalian host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. Novel means have also been found for treating tumors. Augmentation of the host&#39;s defenses against infectious diseases or tumors is achieved by &#39;arming&#39; the host&#39;s cells with a gene encoding the lytic peptide cecropin B. The host&#39;s own leukocytes, other cells involved in resistance to infection, or other cells are transformed, and expression of the gene is induced when needed to combat pathogens. Transfection of hematopoietic stem cells with the cecropin B gene will enhance disease resistance in mammals; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. The transformed cells have the ability to produce and secrete a broad spectrum chemotherapeutic agent which has a systemic effect on certain pathogens, particularly pathogens that might otherwise evade or overcome host defenses. The peptide&#39;s expression preferably induced only in areas of infection, where it will most effectively augment the host&#39;s defense systems. Expression of the exogenous gene does not damage a healthy recipient cell.
The utility model provides an umbilical therapy band for treating chromic urticaria and vitiligo, belonging to a medical article. The utility model is characterized in that the umbilical therapy band is composed of one kummerbund body and one elastic band. The end parts of the kummerbund body and the elastic band are mutually connected, which forms a circle tied with a patient&#39;s abdomen. A paper envelope is seamed on an umbilical therapy body, powder-shaped traditional Chinese medicine of 10 grams are positioned in the paper envelope, the traditional Chinese medicine is aligned with the patient&#39;s umbilical region namely shenque acupoint, and therapy can be carried out by means of the volatilization of medicine. The utility model is used for not less than 20 hours every day, three months is a course of therapy, and medicine is changed once every half month. The utility model is characterized in good curative effect, and no pain.
1. A method of inhibiting melanoma comprising administering to a human in need thereof an effective amount of a compound having the formula I   wherein R&lt;1&gt; and R&lt;3&gt; are independently hydrogen,   wherein Ar is optionally substituted phenyl; R&lt;2&gt; is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt or solvate thereof; alone or in combination with one or more melanoma-inhibiting agents. 2. The method of claim 1 wherein said compound is the hydrochloride salt thereof. 3. The method of claim 1 wherein said compound is   or its hydrochloride salt. 4. The method of claim 1 wherein said administration is in combination with one or more of cisplatin, dacarbazine or carmustine. 5. The method of claim 1 wherein said melanoma is metastatic.
A method for providing medical diagnostic equipment in a patient&#39;s home to permit remote assessment by a medical practitioner is described. A need for a particular diagnostic equipment to be set up in the patient&#39;s home is identified. A request is placed for diagnostic equipment to be allocated to the patient. The diagnostic equipment is dispensed to the patient together with instructions as to how to set up the equipment. The diagnostic equipment is set up in the patient&#39;s home according to the instruction and is used for recording physiological data allowing a remote assessment of the patient. The diagnostic equipment is returned after use and the physiological data is validated by a technician. The physiological data is then analyzed and an assessment of the patient is provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To prevent processing from becoming complicated after medical inspection is entrusted.  &lt;P&gt;SOLUTION: An acceptance server 20 of a data center relays request information to be issued from request origin client terminals 17 and 19 to a request destination client terminal 17, and distributes it to the client terminal 17 of a medical facility (hospitals A to D) designated by the request origin. The acceptance server 20 stores the relayed request information. When the request destination which has accepted the inspection request based on the first request information entrusts another request destination, the acceptance server 20 stores second request information issued by the request destination through the acceptance server 20 as a new request origin to the entrust destination client terminal 17 by associating it with the previous first request information. Therefore, it is possible to easily grasp the request origin, the request destination (entrust origin) which has accepted the inspection request from the request origin, and the entrust destination to which the inspection request has been entrusted from the request destination on the basis of the both request information associated with each other. Thus, the processing is prevented from becoming complicated after the medical inspection is entrusted.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for efficiently extracting GPCR sequences from human genome sequences, thereby comprehensively identifying novel GPCRs.  &lt;P&gt;SOLUTION: An original automatic system for identifying GPCR sequences is disclosed. The system is composed of 3 steps. The 1st step comprises the estimation of a gene, i.e., the translation of a genome sequence to an amino acid sequence. The 2nd step comprises the triple analysis of the amino acid sequence, i.e., the retrieval of a known GPCR data base, the attribution to a motif and a domain and the estimation of a transmembrane helix. The candidate sequences are screened by summing the results of these 3 analyses. The sum is used in the screening stage to maximize the number of the candidate sequences as far as possible. The 3rd step improves the quality of the gene candidates by eliminating duplicate sequences or fusing segment sequences separated by improper estimation.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
In this work we have targeted two aspects of GQDs, Size and ROS to reduce their cytotoxicity. Small size can damage cell organelles and production of ROS (reactive oxygen species) can hamper cell machinery in multiple ways. We have shown that cytotoxicity can be significantly reduced by embedding GQDs inside the PEG matrix rather than creating a thin shell around each GQD. Thin PEG shell around GQD can control ROS production but cannot circumvent the toxicity due to small size. Thus it was essential to solve both the issues. We have used a simple electrochemical method (12h at room temperature) for synthesizing GQDs and embedded them in PEG matrix via a simple one step hydrothermal reaction (24h at 160°C) involving only GQDs, PEG, and deionized water. The P-GQDs formed after hydrothermal reaction show nanoparticles of diameter of ~80-100 nm containing GQDs entrapped in PEG matrix. MTT assay showed significant 60% cells viability at a very high concentration of 5.5 mg/mL of P-GQDs compared to 10-15% viability for C-GQD and H-GQD. ROS production by P-GQDs was least compared to C-GQD and H-GQD in cell free and intracellular ROS assay suggesting involvement of ROS in cytotoxicity. In this work we have solved the issue of cytotoxicity due to &#39;small size&#39; and &#39;ROS generation&#39; without compromising with fluorescence properties of GQDs. P-GQDs was used for bioimaging and drug delivery in HeLa cells. In short we can obtain biocompatible P-GQDs in very short span of time with minimal use of hazardous chemicals and simple methodology.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a &#34;functional food/environmental repairing agent expected to exhibit a decomposition function of various steroids&#34; by using a fermented food such as kimutsi.  &lt;P&gt;SOLUTION: This functional food/environmental repairing agent is provided by utilizing cholesterol-decomposing microorganisms or their cholesterol-decomposing enzymes separated from fermented foods such as the kimutsi, pickles with sake lees, soybean paste, fermented soybean using Bacillus natto by using an accumulative culturing method. Further, on using as the functional food, it may be mixed with a suitable carrier, or has shapes of capsules or a medicinal bags. Also, a method for producing the food by adding the separated &#34;cholesterol-decomposing microorganisms derived from the fermented food or their decomposing enzymes&#34; in the process of producing the fermented food such as the kimutsi, is useful. In such cases, simultaneously adding of either one of lipase and protease or both of them may be allowed. As an object for the decomposition, various steroidal substances such as estrogen, androgen, cortisol, (related to diseases) may be selected.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To suppress elution of calcium ion into water as little as possible by adding and mixing a specified compd. into calcium hydrogenphosphate or its suspension liquid. CONSTITUTION:Calcium hydrogenphosphate is suspended in water, to which a single or mixture compd. selected from among oxalic acid, sodium oxalate, sodium potassium oxalate, potassium oxalate, magnesium oxalate, calcium oxalate, sodium silicate, potassium silicate, magnesium silicate, magnesium calcium silicate and calcium silicate is mixed solely or in combination by &lt;=30wt.% at 10-100 deg.C. After the mixture is stirred for 0.5 to 50 hours, filtered and dried, or, these inorg. salts are mixed in a dry state to calcium hydrogenphosphate so that the surface of calcium hydrogenphosphate is coated with an inorg. salt having negative ions with low solubility than calcium hydrogenphosphate when the inorg. salt is changed into calcium salt. Thus, elution of calcium ion is suppressed. The obtd. calcium hydrogenphosphate is useful as an abrasive for toothpaste.
The invention relates to a method for forming dental impressions using an impression tray (1, 2) having a groove-shaped mould case (15). In an individualisation process step preceding preparation of the impression, a highly viscous curable impression material (11) is applied around the edges (4, 3) of the impression tray, and the impression tray is then pressed with its edges against the mobile mucous membrane. After curing of the highly viscous impression material the impression tray is removed from the jaw together with the impression material. In a subsequent process step, the mould case of the impression tray, which has previously been fully individualised, is filled with a curable impression material of low viscosity, and the impression tray is then pressed onto the jaw with its edges resting against the mobile mucous membranes. The patient is instructed to mobilise the mobile mucous membranes. After curing of the impression material of low viscosity whose maximum final hardness is 30 Shore A the fully individualised impression tray is removed from the jaw together with the impression material. The grooved bottom of the mould case of the impression tray which has previously been fully individualised can be lined with a curable, kneadable material. …&lt;IMAGE&gt;…
FIELD: medicine.SUBSTANCE: invention refers to medicine and can be used for making a drug for removing subcutaneous fat. That is ensured by using a composition containing: at least one phospholipid, at least one glycyrrhizic acid or a glycyrrhizic acid salt, and wherein total content of phospholipids and glycyrrhizic acid or its salts makes 2-80 wt % and a weight ratio of phospholipids and glycyrrhizic acid or its salts makes from 30:1 to 0.5:1. The composition can additionally contain additives. As phospholipid, the composition contains animal or herbal phosphatidylcholine. The composition can also contain glycyrrhizic acid or potassium, sodium, ammonium or magnesium salt of glycyrrhizic acid. As an additive, the composition contains sugar, particularly glucose, or maltose, and/or their derivatives, mannitol, sorbitol or lactose. The composition contains phosphatidylcholine in a total amount of 15 to 98 wt %, preferentially 30 to 98 wt %, more preferentially 50 to 98 wt %, especially preferentially 75 to 98 wt %, and most preferentially 75 to 90 wt % of total content of phospholipids. The composition is used in the dry form, preferentially in the form of lyophilisate prepared by freezing and drying, or in the form of a solution. The composition can contain physiologically acceptable solvents, including water, normal saline, glucose solution, such monohydric alcohols, as ethanol, 2-propanol, n-propanol, such polyatomic alcohols, as glycerol and/or propane diol, such polyglycols, as polyethylene glycol and/or Miglyol, glycerol, formal, dimethylisosorbitol, natural and synthetic oils and/or esters. Diseases of subcutaneous fatty tissue can be particularly related to local fat maldistribution. Fatty tissue tumour decomposition and reduction can be also solved. The drug can be presented in the form of cream, ointment, gel, hydrogel, lotion, paste, powder or solution. Undesired unaesthetic and pathological local fat maldistribution involve lipoedema, adipose growth, abdominal adiposis, cellulites, pseudogynecomasty, &#34;buffalo hump&#34; in HIV-infected patients, panniculitis or nonspecific subcutaneous fat deposition. The preparation is administered by subcutaneous, intra-abdominal, intramuscular or intravenous injection. The administration is implemented by a method specified in a group consisting of ioophoresis, electroporetion and phonophoresis.EFFECT: described invention is successfully used for the above purposes.17 cl, 11 ex, 7 tbl, 11 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a healthcare system that sufficiently ensures the reliability of a target amount of calorie to be presented to a user.  &lt;P&gt;SOLUTION: The healthcare system 100 has a plurality of input terminals 40 and a server apparatus 50 that can communicate with each of the plurality of input terminals 40. When the user starts dieting, the input terminal 40 of the user acquires data for target setting and designation information of the user and transmits the data and information to the server apparatus 50. The data for target setting includes an increased target amount of calorie to be burned, a plurality of types of personal information of the user, an initial body weight, a dietting period, and a target body weight. The server apparatus 50 extracts data of other user corresponding to personal information designated by the received designation information and the received dietting period from a database portion 52, and creates an estimate equation based on the extracted data. The server apparatus 50 then calculates a target amount of consumed calorie to be reduced for the user by using the estimate equation.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain the subject composition having excellent storage stability over a wide range of temperatures, also improved in usability such as to be capable of using a highly polar oil component having been hard to formulate. CONSTITUTION:This water-in-oil emulsified composition comprises (A) pref. 1-50wt.% of a water including oil component capable of including water at &gt;=135wt.% of its own weight when including water at 50 deg.C followed by returning to room temperature, e.g. an oil-soluble N-long chain acyl acidic amino acid mono or diester of the formula X and Y are both sterol&#39;s ester formation residues, or, such that one of them is a sterol&#39;s ester formation residue and the other being H, a 8-30C liquid higher alkyl, or alkenyl or 12-38C solid higher alkyl monohydric alcohol&#39;s ester formation residue; CR is a 8-22C long chain acyl; (n) is 1 or 2), (B) pref. 0.5-3wt.% of a water-swellable clay mineral, e.g. an organomodified clay mineral obtained by treating montmorillonite group or synthetic mica with a quaternary ammonium salt, and (C) water.
Pharmaceutically acceptable preparations of extracellular vesicles derived from activated MSCs are provided. These preparations are essentially free of MSCs, and demonstrate anti- inflammatory inhibiting pharmacological activity in vivo. Methods for using the preparations to prevent the onset of autoimmune diseases are presented. The MSC derived extracellular vesicles are provided in pharmaceutically acceptable preparations with a carrier, such as saline, and may be used to inhibit activation of antigen presenting cells. These preparations may also be used to suppress the development of T helper 1 (Th1) and Th17 cells. The disclosed activated MSC - derived extracellular vesicle preparations are essentially free of MSCs and other cells. Methods and preparations for treating and/or inhibiting the inflammatory response attendant organ transplant, diseases including human uveitis, type 1 diabetes, scleroderma, rheumatoid arthritis, lupus, Sjorgren&#39;s syndrome, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome, multiple sclerosis, anti-glomerular basement membrane disease, and pemphigoid diseases, are also provided.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; and R&lt;3&gt; are II or CH3; X is alkylene derived from 1-7C alkyl) and its hydrohalogenic acid salt. EXAMPLE:dl-alpha-Tocopherol aminoacetic acid ester hydrochloride. USE:A drug. It can be easily hydrolyzed in vivo to form a free tocopherol and is easily soluble in water to enable the preparation of a solution having a concentration of &gt;=100mM. A bile acid salt of formula IV (BA is bile acid) having extremely low hemolytic activity can be produced from the subject compound. PREPARATION:The compound of formula I can be easily produced by conventional esterification of tocopherols of formula II with an aminoalkylcarboxylic acid of formula III or its reactive derivative or their hydrohalogenic acid salt e.g. by directly esterifying in a solvent (e.g. pyridine) in the presence of an active esterification reagent (e.g. dicyclohexylcarbodiimide).
1,201,423. Iron salt-antibiotic compositions. DIAMOND SHAMROCK CORP. 5 Aug., 1968, No. 37329/68. Heading A5B. A stable, compatible, water soluble composition for adding to animal&#39;s drinking water comprises (A) ferric ammonium citrate and at least one antibiotic selected from neomycin sulphate, streptomycin sulphate, a potassium penicillin and tylosin tartrate or (B) ferric pyrophosphate and a potassium penicillin or tylosin phosphate with the proviso that the composition is free from solubilising and stabilising agents; the weight ratio of iron salt to antibiotic being 1:5 to 20:1. Solutions of the composition in water in a weight ratio of 1:80 to 1:2000 are also claimed. Other additives, e.g. vitamins may also be present.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an effective inhibitor of TTK protein kinase, consequently, an effective anticancer agent.  &lt;P&gt;SOLUTION: The compound represented by formula and a related substance thereof (e.g. pharmaceutical composition, TTK inhibitor, etc.) are provided. A new series of compounds having specific characteristics so as to inhibit TTK kinase action and to be especially useful for formulation of a medicine for treating diseases is discovered. The compound is useful for treatment of proliferative diseases like cancer in which TTK kinase generated as any of solid tumor and blood tumor is known to be active, especially colorectal cancer, breast cancer, lung cancer, prostatic cancer, pancreatic cancer, bladder cancer, kidney cancer, similarly useful in diseases like leukemia and lymphoma.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an apparatus and a method for regulating a substance, which flexibly regulates the physical property or state of a substance.  &lt;P&gt;SOLUTION: The apparatus for regulating a substance, which regulates the physical property or state of a substance, includes a terahertz wave generating means 40, a guided wave means 50 and a mechanical stimulus impression means 60. The guided wave means 50 guides a terahertz wave outputted from the terahertz wave generating means 40 and irradiates a substance 10 with the terahertz wave. The mechanical stimulus impression means 60 impresses a mechanical energy on the substance 10. The apparatus for regulating a substance may have a detection means 70 for detecting a terahertz wave from a substance, a database part 80 possessing substance data and a comparison means 90 for comparing substance data obtained from the detection means with data of the database part and determining the physical property or state of a substance. The apparatus for regulating a substance may have a control means 100 that controls at least one of the terahertz wave generating means and the mechanical stimulus impression means based on an output signal from the comparison means so as to regulate an energy impression state to a substance.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a medicine preparation having an action capable of continuously increasing a level of the antihemophilic 8th factor in vivo by using a biologically active specific styptic factor and/or its fraction as an effective ingredient. SOLUTION: In this medicine preparation, von Willebrand&#39;s factor(vWF) and/or a vWF fraction having a prolonged biological half time is used. The vWF and/or the vWF fraction is preferably one having &gt;=20 hours half time in vivo and a multimer structure consisting of singlets. The vWF fraction preferably consists of low molecular weight vWFs having &lt;5 million dalton, especially &lt;3 million dalton. The solution concentration at an administration is preferably 1-1000U/ml of the vWF and/or the vWF fraction. As the vWF, a recombined vWF is especially preferable. The vWF can preferably be fractionated by a chromatographic purification, especially by an ion exchange and/or an affinity chromatography.